Methylguanidine reduces the development of non septic shock induced by zymosan in mice

Life Sciences
Stefania MarzoccoGiuseppina Autore

Abstract

In the present study we evaluate the effect of methylguanidine (MG), a product of protein catabolism, in a model of acute inflammation (zymosan induced inflammation) in mice where oxyradical and nitric oxide (NO) play a crucial role. Our data show that MG, given intraperitoneally at the dose of 30 mg/Kg, inhibits the inflammatory response reducing significantly (P < 0.05) peritoneal exudates formation, mononuclear cell infiltration and histological injury in mice. Furthermore, our data suggests that there is a significant (P < 0.05) reduction in kidney, liver and pancreas injury as demonstrated by the reduction in amylase, lipase, creatinine, AST, ALT, bilirubine and alkaline phosfatase levels. MG is also able to reduce the appearance of nitrotyrosine and of the nuclear enzyme poly (adenosine diphosphate [ADP]-ribose) synthase (PARS) immunoreactivity in the inflamed intestinal and lung tissues. The histological examination revealed a significant reduction in zymosan-induced intestinal and lung damage in MG-treated mice. Taken together, the present results demonstrate that MG exerts potent anti-inflammatory effects on zymosan-induced shock.

References

Mar 1, 1992·The Journal of Surgical Research·I P van BebberR J Goris
Dec 15, 1991·Klinische Wochenschrift·T Yamada, M B Grisham
Aug 1, 1991·Scandinavian Journal of Immunology·E J von AsmuthW A Buurman
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·J S BeckmanB A Freeman
Dec 1, 1989·The Journal of Surgical Research·I P van BebberG Schlag
Aug 1, 1986·Archives of Surgery·R J GorisP H Schillings
Sep 1, 1983·The Journal of Trauma·E FaistG Heberer
Oct 24, 1995·Biochemical and Biophysical Research Communications·M G SalgoW A Pryor
Dec 30, 1993·The New England Journal of Medicine·S Moncada, A Higgs
Mar 1, 1994·Kidney International·R J MacAllisterP Vallance
Feb 9, 1993·European Journal of Pharmacology·J DamasV Bourdon
Nov 20, 1997·The Journal of Clinical Investigation·A B LentschP A Ward
Apr 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·D SalveminiT P Misko
May 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·C SzabóE Kun
Jul 31, 1998·European Journal of Pharmacology·C Szabó
Feb 22, 2001·British Journal of Pharmacology·D SalveminiS Cuzzocrea
Feb 12, 2002·Lipids·L Iuliano
Oct 19, 2002·Nutritional Neuroscience·A V Rao, B Balachandran

❮ Previous
Next ❯

Citations

Oct 8, 2013·PloS One·Simona AdessoStefania Marzocco
Aug 28, 2014·Amino Acids·Ada PopoloStefania Marzocco
Feb 27, 2013·Free Radical Research·A PopoloS Marzocco
Jan 8, 2020·International Journal of Molecular Sciences·Shara Francesca RapaStefania Marzocco
Jan 28, 2021·International Journal of Molecular Sciences·Shara Francesca RapaStefania Marzocco

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here